
|Videos|February 16, 2023
Case 3: Faricimab in a neovascular nAMD patient with persistent fluid
Advertisement
Dr. Khanani discusses how switching to faricimab helped resolve persistent intraretinal and subretinal fluid in a patient and extended treatment intervals leading to decreased patient burden.
Sponsored by Roche
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
FDA expands faricimab label to include treatment of macular edema secondary to retinal vein occlusion beyond 6 months
2
Tattoo-associated uveitis: An emerging eye health challenge
3
Directional OCT provides biomarkers of Parkinson’s Disease in the outer retina
4
FDA grants RMAT designation to RTx-015 optogenetic gene therapy for retinitis pigmentosa
5

























